Zimmermann, PetraPerrett, Kirsten PMessina, Nicole LDonath, SusanRitz, Nicolevan der Klis, Fiona R MCurtis, Nigel2019-10-042019-10-042019-08-012589-53703151726010.1016/j.eclinm.2019.06.010http://hdl.handle.net/10029/623276In total, 471 healthy infants were included. At 7 and 13 months of age, antibodies to the primary course of routine vaccines given at 6 weeks, 4 and 6 months of age (pertussis (pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN)), polio (type 1, 2, 3), Haemophilus influenzae type b (Hib), pneumococcus (serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)) were measured, and at 13 months of age, antibodies to the 12-month routine vaccines (Hib, meningococcus C, measles, mumps and rubella). The seroprotection rates for each vaccine and the geometric mean concentrations (GMC) of antibodies were compared between infants whose mothers did or did not receive dTpa or TIV immunisation during pregnancy.enAdacelAntibodiesBCG, Bacillus Calmette-Guérin vaccineBoostrixCI, confidence intervalFHA, filamentous haemagglutininFIM, fimbriaeFluGMC, geometric mean antibody concentrationGMR, geometric mean antibody ratioHepB, hepatitis BHeterologousHib, Haemophilus influenzae type bHumoralIPV, inactivated polio vaccineIgG, immunoglobulin GImmunisationImmunoglobulinInfluenzaMIS BAIR, Melbourne Infant Study: BCG for Allergy and Infection ReductionMMR, measles-mumps-rubella vaccineMenC, meningococcus type CNon-specificPCV13, 13-valent conjugate pneumococcal vaccinePRN, pertactinPT, pertussis toxinTCV, tetanus-containing vaccineTIV, trivalent inactivated influenza vaccineTitreVaccinationdTpadTpa, diphtheria-tetanus-acellular pertussis vaccineArticleEClinical Medicine 2019; 13:21-30